Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
11 January 2021Website:
http://www.surrozen.comNext earnings report:
09 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Mon, 01 Jul 2024 22:16:20 GMTDividend
Analysts recommendations
Institutional Ownership
SRZN Latest News
SZN-043 is a novel biotherapeutic shown to potentiate Wnt signaling and induce proliferation of hepatocytes in preclinical models Treatment with SZN-043 in the Phase 1a trial was safe and well tolerated in healthy volunteers and patients with a history of liver cirrhosis Phase 1a trial of SZN-043 demonstrated evidence of target engagement and Wnt-pathway mediated pharmacodynamic effects in the liver Enrollment is ongoing in Phase 1b study in severe alcohol-associated hepatitis SOUTH SAN FRANCISCO, Calif., June 10, 2024 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate the Wnt Pathway for tissue repair and regeneration, presented a poster on the preliminary results of a Phase 1a study of SZN-043, a novel R-Spondin mimetic, in healthy volunteers and subjects with liver cirrhosis on June 8, 2024 at the 2024 European Association for the Study of the Liver (EASL) in Milan (LINK: HERE).
Surrozen, Inc. (SRZN) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
What type of business is Surrozen?
Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair and regeneration. It is developing tissue-specific antibodies with application across various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043 a tissue-specific R-spondin mimetic for the treatment of severe liver disease; and SZN-1326, a bi-specific full-length human antibody that directly modulates Wnt signaling in target tissue by binding to particular Frizzled and LRP receptors that are expressed in intestinal crypts. Surrozen, Inc. was founded in 2015 and is headquartered in South San Francisco, California.
What sector is Surrozen in?
Surrozen is in the Healthcare sector
What industry is Surrozen in?
Surrozen is in the Biotechnology industry
What country is Surrozen from?
Surrozen is headquartered in United States
When did Surrozen go public?
Surrozen initial public offering (IPO) was on 11 January 2021
What is Surrozen website?
https://www.surrozen.com
Is Surrozen in the S&P 500?
No, Surrozen is not included in the S&P 500 index
Is Surrozen in the NASDAQ 100?
No, Surrozen is not included in the NASDAQ 100 index
Is Surrozen in the Dow Jones?
No, Surrozen is not included in the Dow Jones index
When does Surrozen report earnings?
The next expected earnings date for Surrozen is 09 August 2024